🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

198 results for “Novartis Ophthalmics Europe” Clear

  1. TISAGENLECLEUCEL

    Novartis Ophthalmics Europe

    High-risk B-cell acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  2. TNO155, JDQ443, TNO155, VDT482/ BGB-A317, JDQ443, TNO155, TNO155

    Novartis Ophthalmics Europe

    Advance solid tumors harboring the KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  3. TOCILIZUMAB, FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE

    Novartis Ophthalmics Europe

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  4. TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEE011, TEMOZOLOMIDE, TEMOZOLOMIDE

    Novartis Ophthalmics Europe

    Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)

    phase 2 small molecule active

    1 trial

  5. VAY736, ARTICAINE, COMBINATIONS, TENOFOVIR ALAFENAMIDE, PERFLUTREN, PHOSPHOLIPID MICROSPHERES, ENTECAVIR , -

    Novartis Ophthalmics Europe

    Sjögren's syndrome

    phase 2 small molecule active

    1 trial

  6. VAY736, Placebo Solution for injection or infusion 0 mg/1 mL

    Novartis Ophthalmics Europe

    Moderate to severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  7. VAY736, TENOFOVIR ALAFENAMIDE, ENTECAVIR , -, VAY736, VAY736, TENOFOVIR DISOPROXIL

    Novartis Ophthalmics Europe

    Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus

    phase 2 small molecule active

    1 trial

  8. VHB937, Placebo 00 mg/ 00mL, concentrate for solution for infusion (Placebo to VHB937)

    Novartis Ophthalmics Europe

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  9. YTB323, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, TOCILIZUMAB

    Novartis Ophthalmics Europe

    Non-active Progressive Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  10. YTB323, Flebogamma DIF 50 mg/ml solution for infusion, TOCILIZUMAB, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Novartis Ophthalmics Europe

    Treatment-resistant generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  11. A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.

    Novartis Ophthalmics Europe

    Glioblastoma

    phase 1 other active

    1 trial

  12. A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease

    Novartis Ophthalmics Europe

    Chronic Kidney Disease

    phase 1 other active

    1 trial

  13. A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations

    Novartis Ophthalmics Europe

    Advanced malignancies that harbor IDH1R132 mutations

    phase 1 other active

    1 trial

  14. A Phase I, open-label, non-randomized study to assess the absorption, distribution, metabolism and excretion (ADME) and pharmacokinetics of LTP001 following a single oral dose of [14C]LTP001 in healthy male participants

    Novartis Ophthalmics Europe

    Healthy volunteers

    phase 1 other active

    1 trial

  15. A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants

    Novartis Ophthalmics Europe

    Parkinson’s Disease

    phase 1 other active

    1 trial

  16. A clinical study to evaluate the efficacy of ceritinib in combination with nivolumab in patients with ALK positive lung cancer

    Novartis Ophthalmics Europe

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  17. A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer

    Novartis Ophthalmics Europe

    Patients with advanced malignancies

    phase 1 other active

    1 trial

  18. A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer

    Novartis Ophthalmics Europe

    Advanced Malignancies and Hepatic Impairment

    phase 1 other active

    1 trial

  19. A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of HJB647 in healthy participants and otherwise healthy participants with elevated blood pressure, with an open-label CYP3A inhibitor drug-drug interaction part

    Novartis Ophthalmics Europe

    Heart failure (HF)

    phase 1 other active

    1 trial

  20. A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors

    Novartis Ophthalmics Europe

    Advanced solid tumors

    phase 1 other active

    1 trial

  21. A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors

    Novartis Ophthalmics Europe

    Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)

    phase 1 other active

    1 trial

  22. A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

    Novartis Ophthalmics Europe

    Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)

    phase 1 other active

    1 trial

  23. A phase I study of [68Ga]Ga-DWJ155 in patients with advanced breast and NSCLC cancers

    Novartis Ophthalmics Europe

    Advanced breast cancer and advanced NSCLC

    phase 1 other active

    1 trial

  24. A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

    Novartis Ophthalmics Europe

    Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources